Literature DB >> 30528824

The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction.

Ellen Witte-Händel1, Kerstin Wolk2, Athanasia Tsaousi3, Marie Luise Irmer3, Rotraut Mößner4, Orr Shomroni5, Thomas Lingner5, Katrin Witte6, Desiree Kunkel7, Gabriela Salinas5, Stefan Jodl8, Nicole Schmidt8, Wolfram Sterry9, Hans-Dieter Volk10, Evangelos J Giamarellos-Bourboulis11, Anna Pokrywka9, Wolf-Dietrich Döcke8, Sylke Schneider-Burrus9, Robert Sabat12.   

Abstract

Hidradenitis suppurativa (HS) (also designated acne inversa) is a chronic inflammatory disease characterized by painful purulent skin lesions and progressive destruction of skin architecture. Despite the high burden for the patients, pathogenetic pathways underlying HS alterations remain obscure. When we examined the HS cytokine pattern, IL-1β turned out to be a highly prominent cytokine, overexpressed even compared with psoriatic lesions. Analyses of IL-1β-induced transcriptome in various cell types showed overlapping profiles, with upregulations of molecules causing immune cell infiltration and extracellular matrix degradation, and of specific cytokines including IL-6, IL-32, and IL-36. Matching cellular IL-1 receptor levels, dermal fibroblasts showed both the strongest and broadest IL-1β response, which was not clearly shared or strengthened by other cytokines. The IL-1β signature was specifically present in HS lesions and could be reversed by application of IL-1 receptor antagonist. Search for blood parameters associated with IL-1β pathway activity in HS identified serum amyloid A, which was synergistically induced by IL-1β and IL-6 in hepatocytes. Consequently, strongly elevated blood serum amyloid A levels in HS correlated positively with the extent of inflammatory skin alterations. In summary, the IL-1β pathway represents a pathogenetic cascade, whose activity may be therapeutically targeted and monitored by blood SAA levels.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30528824     DOI: 10.1016/j.jid.2018.11.018

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  39 in total

1.  Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa.

Authors:  K Navrazhina; J W Frew; J G Krueger
Journal:  Br J Dermatol       Date:  2019-12-03       Impact factor: 9.302

2.  Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System.

Authors:  Georgios Kokolakis; Kerstin Wolk; Sylke Schneider-Burrus; Stefanie Kalus; Sebastian Barbus; Susana Gomis-Kleindienst; Robert Sabat
Journal:  Dermatology       Date:  2020-07-01       Impact factor: 5.366

Review 3.  Botulinum toxin type A for the management of hidradenitis suppurativa.

Authors:  Huanhuan Qu; Lin Gao
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 4.  [Pathogenesis of hidradenitis suppurativa/acne inversa].

Authors:  G Nikolakis; G Kokolakis; K Kaleta; K Wolk; R Hunger; R Sabat; C C Zouboulis
Journal:  Hautarzt       Date:  2021-07-06       Impact factor: 0.751

5.  Increased presence and differential molecular imprinting of transit amplifying cells in psoriasis.

Authors:  Katrin Witte; Karsten Jürchott; Demetrios Christou; Jochen Hecht; Gabriela Salinas; Ulrike Krüger; Oliver Klein; Georgios Kokolakis; Ellen Witte-Händel; Rotraut Mössner; Hans-Dieter Volk; Kerstin Wolk; Robert Sabat
Journal:  J Mol Med (Berl)       Date:  2019-12-12       Impact factor: 4.599

6.  The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.

Authors:  John W Frew; Kristina Navrazhina; David Grand; Mary Sullivan-Whalen; Patricia Gilleaudeau; Sandra Garcet; Jonathan Ungar; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2020-05-13       Impact factor: 11.527

Review 7.  IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa.

Authors:  J M Fletcher; B Moran; A Petrasca; C M Smith
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

Review 8.  Hidradenitis suppurativa.

Authors:  Robert Sabat; Gregor B E Jemec; Łukasz Matusiak; Alexa B Kimball; Errol Prens; Kerstin Wolk
Journal:  Nat Rev Dis Primers       Date:  2020-03-12       Impact factor: 52.329

9.  Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients.

Authors:  Sylke Schneider-Burrus; Athanasia Tsaousi; Sebastian Barbus; Johannes Huss-Marp; Katrin Witte; Kerstin Wolk; Björn Fritz; Robert Sabat
Journal:  Front Med (Lausanne)       Date:  2021-04-27

10.  The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.

Authors:  Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger
Journal:  J Am Acad Dermatol       Date:  2021-07-30       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.